Literature DB >> 21373926

Quality of life and illness beliefs in individuals with early psychosis.

Kate Theodore1, Sonia Johnson, Anna Chalmers-Brown, Rhianne Doherty, Chris Harrop, Lyn Ellett.   

Abstract

PURPOSE: Quality of life (QoL) has become an important outcome measure in early psychosis. This study examined associations between illness beliefs (how individuals perceive their mental health problems), symptom factors and QoL in an early psychosis population.
METHODS: Eighty-one individuals with early psychosis completed a battery of questionnaires measuring QoL, illness perceptions, psychotic and affective symptoms.
RESULTS: QoL was significantly associated with certain illness beliefs, namely treatment control and consequences of psychosis. Lower levels of QoL were associated with higher depression, anxiety and general psychopathology. QoL was found to be predicted by key illness beliefs.
CONCLUSIONS: Causality has not been fully established, but these results suggest that beliefs about mental health problems may have a direct impact on outcome, and point towards possible targets for intervention, such as challenging illness-related appraisals. This is consistent with both general cognitive models of psychosis, and Cognitive Behaviour Therapy for this client group.

Entities:  

Mesh:

Year:  2011        PMID: 21373926     DOI: 10.1007/s00127-011-0360-1

Source DB:  PubMed          Journal:  Soc Psychiatry Psychiatr Epidemiol        ISSN: 0933-7954            Impact factor:   4.328


  29 in total

1.  Determinants of quality of life at first presentation with schizophrenia.

Authors:  S Browne; M Clarke; M Gervin; J L Waddington; C Larkin; E O'Callaghan
Journal:  Br J Psychiatry       Date:  2000-02       Impact factor: 9.319

2.  A cognitive model of the positive symptoms of psychosis.

Authors:  P A Garety; E Kuipers; D Fowler; D Freeman; P E Bebbington
Journal:  Psychol Med       Date:  2001-02       Impact factor: 7.723

3.  The impact of beliefs about mental health problems and coping on outcome in schizophrenia.

Authors:  F Lobban; C Barrowclough; S Jones
Journal:  Psychol Med       Date:  2004-10       Impact factor: 7.723

4.  CBT and recovery from psychosis in the ISREP trial: mediating effects of hope and positive beliefs on activity.

Authors:  Joanne Hodgekins; David Fowler
Journal:  Psychiatr Serv       Date:  2010-03       Impact factor: 3.084

Review 5.  Measuring the quality of life of severely mentally ill people using the Lancashire Quality of Life Profile.

Authors:  J P Oliver; P J Huxley; S Priebe; W Kaiser
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1997-02       Impact factor: 4.328

6.  Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression.

Authors:  Kang Sim; Rathi Mahendran; Samuel G Siris; Stephan Heckers; Siow Ann Chong
Journal:  Psychiatry Res       Date:  2004-12-15       Impact factor: 3.222

7.  Assessing cognitive representations of mental health problems. I. The illness perception questionnaire for schizophrenia.

Authors:  Fiona Lobban; Christine Barrowclough; Steven Jones
Journal:  Br J Clin Psychol       Date:  2005-06

8.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

9.  An RCT of early intervention in psychosis: Croydon Outreach and Assertive Support Team (COAST).

Authors:  Elizabeth Kuipers; Frank Holloway; Sophia Rabe-Hesketh; Lakshika Tennakoon
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2004-05       Impact factor: 4.328

10.  Unemployment, social isolation, achievement-expectation mismatch and psychosis: findings from the AESOP Study.

Authors:  Ulrich A Reininghaus; Craig Morgan; Jayne Simpson; Paola Dazzan; Kevin Morgan; Gillian A Doody; Dinesh Bhugra; Julian Leff; Peter Jones; Robin Murray; Paul Fearon; Tom K J Craig
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-05-16       Impact factor: 4.328

View more
  7 in total

1.  Understanding reduced activity in psychosis: the roles of stigma and illness appraisals.

Authors:  Anna Moriarty; Suzanne Jolley; Margie M Callanan; Philippa Garety
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-02-25       Impact factor: 4.328

2.  Randomized trial estimating effects of hypnosis versus progressive muscle relaxation on medical students' test anxiety and attentional bias.

Authors:  Yang Zhang; Xin-Xin Yang; Jing-Yi Luo; Meng Liang; Ni Li; Qian Tao; Li-Jun Ma; Xiao-Ming Li
Journal:  World J Psychiatry       Date:  2022-06-19

3.  Causal attribution and illness perception: a cross-sectional study in Mexican patients with psychosis.

Authors:  Lizzette Gómez-de-Regil
Journal:  ScientificWorldJournal       Date:  2014-12-01

Review 4.  Relationship Between Illness Representations, Psychosocial Adjustment, and Treatment Outcomes in Mental Disorders: A Mini Review.

Authors:  Priscillia Averous; Elodie Charbonnier; Lionel Dany
Journal:  Front Psychol       Date:  2020-06-12

5.  Relationship of subjective quality of life with symptomatology, neurocognition and psychosocial functioning in first-episode psychosis: a structural equation modelling approach.

Authors:  Sandra Chi Yiu Wong; Wing Chung Chang; Christy Lai Ming Hui; Sherry Kit Wa Chan; Edwin Ho Ming Lee; Yi Nam Suen; Eric Yu Hai Chen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-07-25       Impact factor: 5.270

6.  Insight and illness perception in Mexican patients with psychosis.

Authors:  Lizzette Gómez-de-Regil
Journal:  Schizophr Res Cogn       Date:  2015-03-05

7.  The U&I study: study protocol for a feasibility randomised controlled trial of a pre-cognitive behavioural therapy digital 'informed choice' intervention to improve attitudes towards uptake and implementation of CBT for psychosis.

Authors:  Kathryn Greenwood; Katie Alford; Iain O'Leary; Emmanuelle Peters; Amy Hardy; Kate Cavanagh; Andy P Field; Richard de Visser; David Fowler; Matthew Davies; Alexandra Papamichail; Philippa Garety
Journal:  Trials       Date:  2018-11-20       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.